Clinical Question
Does the synthetic Growth Hormone Releasing Hormone (GHRH) analog CJC-1295 safely sustain elevated levels of Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) in human subjects?
Evidence Snapshot
- Peptide Type: Synthetic 30-amino acid GHRH analog with Drug Affinity Complex (DAC).
- Evidence Grade: B-
- Regulatory Status: Not FDA approved; Phase II clinical development discontinued.
- Key Pharmacological Outcome: Dose-dependent GH increase (2-10x) for 6+ days; half-life extended to 6-8 days.
- Safety Outcome: Phase II trial halted following a participant death.
- Clinical Trials: One Phase II study (ConjuChem) listed as discontinued.
What the Research Shows
CJC-1295 was developed as a long-acting secretagogue designed to increase systemic levels of GH and IGF-1. Clinical data indicates that the peptide successfully increases GH secretion by 2 to 10 times for a duration exceeding six days. Unlike some earlier analogs, research suggests that CJC-1295 preserves the natural pulsatile pattern of growth hormone release rather than causing a static elevation.
Despite these pharmacological effects on hormone levels, the clinical development of CJC-1295 was halted. A Phase II trial conducted by ConjuChem was discontinued after a participant death occurred during the study. Consequently, there was no further development of the compound for clinical use. Furthermore, the available research does not provide any data from randomized controlled trials (RCTs) regarding body composition changes or athletic performance outcomes.
Regulatory records indicate that the FDA has issued warning letters (e.g., to Tailor Made in 2020) regarding the substance. Additionally, the FDA has cited safety concerns including increased heart rate. The peptide was nominated for 503A pharmacy compounding but was subsequently removed from consideration in September 2024.
Mechanism
CJC-1295 functions as a GHRH analog that stimulates sustained, dose-dependent secretion of GH and IGF-1. Its prolonged duration of action is attributed to two primary structural features provided in the clinical data:
- Drug Affinity Complex (DAC): The peptide utilizes DAC to covalently bind to endogenous albumin. This binding significantly extends the peptide's half-life to 6-8 days.
- Enzymatic Resistance: The molecular structure is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), an enzyme that typically breaks down GHRH analogs.
By leveraging these mechanisms, the peptide maintains its ability to stimulate GH release while preserving the physiological pulsatile pattern of secretion.
Limitations of the Evidence
The primary limitation of the evidence for CJC-1295 is the abrupt cessation of clinical research. Because Phase II trials were discontinued following a participant death, there is a complete lack of long-term safety and efficacy data.
There is a notable evidence gap regarding functional outcomes; specifically, there are no randomized controlled trials evaluating the peptide's impact on body composition or physical performance. Furthermore, clinical interpretation is frequently complicated by the conflation of CJC-1295 (which contains the Drug Affinity Complex) with Mod GRF 1-29 (often referred to as CJC-1295 without DAC), which is a distinct entity. Finally, current regulatory status reflects significant safety concerns, with the FDA highlighting issues such as increased heart rate and the removal of the peptide from compounding nominations.
Clinical Takeaway
CJC-1295 demonstrates a potent ability to extend the half-life of GHRH stimulation and increase GH/IGF-1 levels for several days through its albumin-binding mechanism. However, its clinical relevance is severely restricted by its discontinued status following a participant death in Phase II trials and the absence of data regarding body composition or performance. The FDA currently lists safety concerns including tachycardia, and the peptide is not approved for clinical use.
Sources
- TruthTides Peptide Database: CJC-1295 [Grade: B-]
- Clinical Trial Record: 7d0b97b8-52eb-4026-a3ee-9f7170ade29d (Phase II, Discontinued)
- Regulatory Status Record: 1a160b34-1002-4213-9a8a-95697b6004d8 (FDA status and 503A history)
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.